Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 13/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13466610 | 0.98 | SLC9A3 (0.70) | SLC9A3 | |
| SCHEMBL16638578 | 0.97 | SLC9A3 (0.70) | SLC9A3 | |
| SCHEMBL16479199 | 0.97 | SLC9A3 (0.70) | SLC9A3 | |
| SCHEMBL13285899 | 0.96 | SLC9A3 (0.68) | SLC9A3 | |
| SCHEMBL13276389 | 0.92 | SLC9A3 (0.71) | SLC9A3 | |
| SCHEMBL20362304 | 0.92 | SLC9A3 (0.71) | SLC9A3 | |
| SCHEMBL13276285 | 0.92 | SLC9A3 (0.75) | SLC9A3 | |
| SCHEMBL13449852 | 0.91 | SLC9A3 (0.73) | SLC9A3 | |
| SCHEMBL16638244 | 0.91 | SLC9A3 (0.73) | SLC9A3 | |
| SCHEMBL20362306 | 0.91 | SLC9A3 (0.72) | SLC9A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250067907-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-4397366-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3661945-B1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX INC (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | ARDELYX, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-2384318-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2384318-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9408840-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | ARDELYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408840-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | ARDELYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | ARDELYX, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | ARDELYX, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-9006281-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130274285-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC | 2013-10-17 | — | — | US | disclosed |
| US-8541448-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274285-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A2, SLC10A1, SLC9A2 | SLC9A3 8/4885 |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | SLC9A1, SLC9A2, SLC10A2 | SLC9A3 5/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | SLC9A3 22/4885 |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | SLC9A3 6/4885 |
| US-20250067907-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | SLC9A3 22/4885 |
| US-11768319-B2 | Glycyrrhetinic acid derivatives for treating hyperkalemia | HSD11B2, HSD11B1, HSD3B2 | SLC9A3 264/4885 |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | SLC9A3 4/4885 |
| US-20230273354-A1 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | GRHPR, REN, GRK5 | SLC9A3 141/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | SLC9A3 244/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | SLC9A3 4/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | SLC9A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.